Development and Evaluation of a National Reference Panel of HIV-1 Protease and Reverse Transcriptase Drug-resistance Mutations for HIV-1 Genotypic Resistance Assays in China

Overview

Journal Mol Diagn Ther

Specialties Molecular Biology
Pathology
Pharmacology

Date 2010 Feb 4

PMID 20121288

Citations 3

Authors

Sihong Xu

Jingyun Li

Zuoyi Bao

Hui Xing

Ping Zhong

Hanping Li

Haiwei Zhou

Xinping Li

Sharon Wu

Aijing Song

Xiuhua Li

Jianhui Nie

Youchun Wang

Affiliations

Soon will be listed here.

Abstract

Background: Transmission of antiretroviral drug-resistant strains of HIV-1 has a major impact on the success of HIV treatment regimens in most countries where antiretroviral therapy (ART) is available. It is now recommended that HIV-1 drug resistance be monitored in order to recommend appropriate therapy for infected ART-naïve individuals, or when choosing a new regimen for those patients not responding to ART. Commercial assays for the analysis of HIV-1 genotypic resistance have been approved by the US FDA. In China, several laboratories and research enterprises have been developing related assays, but at present, no systematic standardization or quality control for genotypic resistance assays has been established in China. A national reference panel is needed to evaluate and control the quality of HIV-1 genotype resistance assays in China.

Methods: A panel of five HIV-1 stocks (G1, G2, G3, G4, and G5) with well-characterized drug resistance was used to evaluate the resistance-mutation inclusivity of HIV-1 clades prevalent in China. Six samples (GS1-GS6) were used to evaluate the limit of detection (LOD) for the viral load levels, and five samples (GSS1-GSS3, GSS5, and GSS6) were used to evaluate the LOD for the percentages of mutant species within the range of detection. The samples were evaluated by five separate laboratories using one or two methods each, generating seven datasets in all.

Results: In samples G1-G5, which were used to evaluate inclusivity of HIV-1 clades, 92.86-100%, 16.67-83.33% and 4.17-8.33% of the most, intermediately, and least common resistance mutations, respectively, were reported by the seven datasets. For the LOD samples, four of the seven datasets reported correct resistance mutations in samples with minimal viral loads of >2 x 10(3) copies/mL, as well as in samples with >40% of mutants and viral loads of about 1 x 10(4) copies/mL; the other three tests did not amplify the target region or identify the mutants.

Conclusions: The results were quite variable between different tests. The panel of HIV-1 genotypic resistance could be used as a control for resistance testing in China.

Citing Articles

HIV-1 diversity and drug-resistant mutations in infected individuals in Changchun, China.

Yan M, Zhao K, Du J, Li L, Wu D, Xu S PLoS One. 2014; 9(6):e100540.

PMID: 24945273 PMC: 4063969. DOI: 10.1371/journal.pone.0100540.

Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.

Land S, Zhou J, Cunningham P, Sohn A, Singtoroj T, Katzenstein D J Int AIDS Soc. 2013; 16:18580.

PMID: 23845227 PMC: 3709369. DOI: 10.7448/IAS.16.1.18580.

Comparative evaluation of the ViroSeq™ HIV-1 genotyping system and an in-house method for analysis of HIV-1 drug-resistance mutations in China.

Xu S, Zhong P, Li J, Song A, Li H, Nie J Mol Diagn Ther. 2011; 15(1):41-52.

PMID: 21469769 DOI: 10.1007/BF03257192.

References

Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E . Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005; 192(6):958-66. DOI: 10.1086/432916. View

Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, Alcami J . A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol. 2006; 79(2):127-37. DOI: 10.1002/jmv.20770. View

Perrin L, Telenti A . HIV treatment failure: testing for HIV resistance in clinical practice. Science. 1998; 280(5371):1871-3. DOI: 10.1126/science.280.5371.1871. View

Brenner B, Wainberg M, Salomon H, Rouleau D, Dascal A, Spira B . Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents. 2000; 16(4):429-34. DOI: 10.1016/s0924-8579(00)00270-3. View

Chaix M, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C . Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003; 17(18):2635-43. DOI: 10.1097/00002030-200312050-00011. View

Shafer R, Jung D, Betts B . Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med. 2000; 6(11):1290-2. PMC: 2582445. DOI: 10.1038/81407. View

Zhong P, Pan Q, Ning Z, Xue Y, Gong J, Zhen X . Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses. 2007; 23(7):847-56. DOI: 10.1089/aid.2006.0196. View

Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C . Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 1999; 37(7):2291-6. PMC: 85140. DOI: 10.1128/JCM.37.7.2291-2296.1999. View

Shafer R, Warford A, Winters M, GONZALES M . Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J Virol Methods. 2000; 86(2):143-53. DOI: 10.1016/s0166-0934(00)00144-0. View

10.

Degruttola V, Dix L, DAquila R, Holder D, Phillips A, Ait-Khaled M . The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000; 5(1):41-8. DOI: 10.1177/135965350000500112. View

11.

Hirsch M, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, DAquila R . Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003; 37(1):113-28. DOI: 10.1086/375597. View

12.

Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P . Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353(9171):2195-9. DOI: 10.1016/s0140-6736(98)12291-2. View

13.

Hirsch M, Gunthard H, Schapiro J, Brun-Vezinet F, Clotet B, Hammer S . Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008; 47(2):266-85. DOI: 10.1086/589297. View

14.

Maes B, Schrooten Y, Snoeck J, Derdelinckx I, Van Ranst M, Vandamme A . Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods. 2004; 119(1):45-9. DOI: 10.1016/j.jviromet.2004.02.005. View

15.

Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Bruun Jorgensen L . Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr. 2005; 40(5):505-11. DOI: 10.1097/01.qai.0000186361.42834.61. View

16.

Yerly S, Kaiser L, Race E, Bru J, Clavel F, Perrin L . Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 1999; 354(9180):729-33. DOI: 10.1016/S0140-6736(98)12262-6. View

17.

Korn K, Reil H, Walter H, Schmidt B . Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol. 2003; 41(8):3559-65. PMC: 179843. DOI: 10.1128/JCM.41.8.3559-3565.2003. View

18.

Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J . Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol. 2004; 78(4):1718-29. PMC: 369469. DOI: 10.1128/jvi.78.4.1718-1729.2004. View

19.

Huang D, Eshleman S, Brambilla D, Palumbo P, Bremer J . Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J Clin Microbiol. 2003; 41(7):3265-72. PMC: 165383. DOI: 10.1128/JCM.41.7.3265-3272.2003. View

20.

Little S, Holte S, Routy J, Daar E, Markowitz M, Collier A . Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002; 347(6):385-94. DOI: 10.1056/NEJMoa013552. View